| Xianglin Yuan. Chinese expert consensus on managing thrombocytopenia in patients with cancer and liver injury. Oncol Transl Med, 2023, 9: 1-14. |
| Chinese expert consensus on managing thrombocytopenia in patients with cancer and liver injury |
| Chinese expert consensus on managing thrombocytopenia in patients with cancer and liver injury |
| Received:February 15, 2023 Revised:February 15, 2023 |
| DOI：10.1007/s10330-023-0628-8 |
| 中文关键词: cancer; liver disease; liver injury; thrombocytopenia; expert consensus |
| 英文关键词: cancer; liver disease; liver injury; thrombocytopenia; expert consensus |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Xianglin Yuan* | Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology | xlyuan@tjh.tjmu.edu.cn |
|
| Hits: 3779 |
| Download times: 4558 |
| 中文摘要: |
| Thrombocytopenia and liver injury are serious clinical problems in patients with cancer. The etiology
of thrombocytopenia in patients with cancer and liver injury (TCLI) is complicated. Managing cancer
therapy-induced thrombocytopenia has gradually become standardized, and managing liver injury-associated thrombocytopenia has become more effective with the approval and marketing of relevant
drugs. However, the optimal strategy for managing thrombocytopenia in patients with cancer and liver
injury remains unclear, and the superposition of thrombocytopenia and liver injury further increases
the difficulty of cancer treatment. Therefore, the Committee of Cancer Support Therapy of the Chinese
Anti-Cancer Association has organized experts to analyze and discuss relevant literature to form a
Chinese expert consensus on managing thrombocytopenia in patients with cancer and liver injury
(2022 Edition) to guide clinical practice. |
| 英文摘要: |
| Thrombocytopenia and liver injury are serious clinical problems in patients with cancer. The etiology
of thrombocytopenia in patients with cancer and liver injury (TCLI) is complicated. Managing cancer
therapy-induced thrombocytopenia has gradually become standardized, and managing liver injury-associated thrombocytopenia has become more effective with the approval and marketing of relevant
drugs. However, the optimal strategy for managing thrombocytopenia in patients with cancer and liver
injury remains unclear, and the superposition of thrombocytopenia and liver injury further increases
the difficulty of cancer treatment. Therefore, the Committee of Cancer Support Therapy of the Chinese
Anti-Cancer Association has organized experts to analyze and discuss relevant literature to form a
Chinese expert consensus on managing thrombocytopenia in patients with cancer and liver injury
(2022 Edition) to guide clinical practice. |
|
View Full Text
Download reader HTML全文 |
| Close |